Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?

Du-Bois Asante, Leslie Calapre, Melanie Ziman, Tarek Meniawy, Elin S Gray

Research output: Contribution to journalShort survey

Abstract

Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated complications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown promising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in many cancer types. In ovarian cancer (OC), CTC and ctDNA analysis allow comprehensive molecular profiling of the primary, metastatic and recurrent tumors. These biomarkers also correlate with overall tumor burden and thus, they provide minimally-invasive means for patient monitoring during clinical course to ascertain therapy response and timely treatment modification in the context of disease relapse. Here, we review recent reports of the potential clinical value of CTC and ctDNA in OC, expatiating on their use in diagnosis and prognosis. We critically appraise the current evidence, and discuss the issues that still need to be addressed before liquid biopsies can be implemented in routine clinical practice for OC management.

Original languageEnglish
Pages (from-to)59-71
Number of pages13
JournalCancer Letters
Volume468
DOIs
Publication statusPublished - 1 Jan 2020

Fingerprint

Circulating Neoplastic Cells
Ovarian Neoplasms
Biopsy
DNA
Neoplasms
Biomarkers
Physiologic Monitoring
Tumor Burden
Therapeutics
Recurrence

Cite this

@article{545dd4159adc41d4a2f26cca38fbd9b2,
title = "Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?",
abstract = "Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated complications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown promising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in many cancer types. In ovarian cancer (OC), CTC and ctDNA analysis allow comprehensive molecular profiling of the primary, metastatic and recurrent tumors. These biomarkers also correlate with overall tumor burden and thus, they provide minimally-invasive means for patient monitoring during clinical course to ascertain therapy response and timely treatment modification in the context of disease relapse. Here, we review recent reports of the potential clinical value of CTC and ctDNA in OC, expatiating on their use in diagnosis and prognosis. We critically appraise the current evidence, and discuss the issues that still need to be addressed before liquid biopsies can be implemented in routine clinical practice for OC management.",
author = "Du-Bois Asante and Leslie Calapre and Melanie Ziman and Tarek Meniawy and Gray, {Elin S}",
year = "2020",
month = "1",
day = "1",
doi = "10.1016/j.canlet.2019.10.014",
language = "English",
volume = "468",
pages = "59--71",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier",

}

Liquid biopsy in ovarian cancer using circulating tumor DNA and cells : Ready for prime time? / Asante, Du-Bois; Calapre, Leslie; Ziman, Melanie; Meniawy, Tarek; Gray, Elin S.

In: Cancer Letters, Vol. 468, 01.01.2020, p. 59-71.

Research output: Contribution to journalShort survey

TY - JOUR

T1 - Liquid biopsy in ovarian cancer using circulating tumor DNA and cells

T2 - Ready for prime time?

AU - Asante, Du-Bois

AU - Calapre, Leslie

AU - Ziman, Melanie

AU - Meniawy, Tarek

AU - Gray, Elin S

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated complications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown promising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in many cancer types. In ovarian cancer (OC), CTC and ctDNA analysis allow comprehensive molecular profiling of the primary, metastatic and recurrent tumors. These biomarkers also correlate with overall tumor burden and thus, they provide minimally-invasive means for patient monitoring during clinical course to ascertain therapy response and timely treatment modification in the context of disease relapse. Here, we review recent reports of the potential clinical value of CTC and ctDNA in OC, expatiating on their use in diagnosis and prognosis. We critically appraise the current evidence, and discuss the issues that still need to be addressed before liquid biopsies can be implemented in routine clinical practice for OC management.

AB - Liquid biopsies hold the potential to inform cancer patient prognosis and to guide treatment decisions at the time when direct tumor biopsy may be impractical due to its invasive nature, inaccessibility and associated complications. Specifically, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) have shown promising results as companion diagnostic biomarkers for screening, prognostication and/or patient surveillance in many cancer types. In ovarian cancer (OC), CTC and ctDNA analysis allow comprehensive molecular profiling of the primary, metastatic and recurrent tumors. These biomarkers also correlate with overall tumor burden and thus, they provide minimally-invasive means for patient monitoring during clinical course to ascertain therapy response and timely treatment modification in the context of disease relapse. Here, we review recent reports of the potential clinical value of CTC and ctDNA in OC, expatiating on their use in diagnosis and prognosis. We critically appraise the current evidence, and discuss the issues that still need to be addressed before liquid biopsies can be implemented in routine clinical practice for OC management.

U2 - 10.1016/j.canlet.2019.10.014

DO - 10.1016/j.canlet.2019.10.014

M3 - Short survey

VL - 468

SP - 59

EP - 71

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -